Lexicon Pharmaceuticals (LXRX) Non-Current Debt (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Non-Current Debt of $49.7 million for Q1 2026, down 15.28% year-over-year from $58.6 million in Q1 2025, and up 0.56% quarter-over-quarter from $49.4 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Non-Current Debt (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Non-Current Debt for 16 consecutive years, with $49.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt fell 15.28% year-over-year to $49.7 million; the TTM figure through Mar 2026 stood at $49.7 million (down 15.28% YoY), while the FY2025 annual figure was $49.4 million, down 50.74% from the prior year.
- Non-Current Debt rose to $49.7 million in Q1 2026 per LXRX's latest filing, from $49.4 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $100.3 million in Q4 2024 and bottomed at $23.5 million in Q1 2022.
- Historically, Non-Current Debt has averaged $66.8 million across 5 years, with a median of $56.5 million in 2025.
- Annual changes were most pronounced in 2023 — Non-Current Debt soared 318.64% — and 2025, when it slumped 50.74%.
- Lexicon Pharmaceuticals' Non-Current Debt stood at $48.6 million in 2022, then surged by 104.84% to $99.5 million in 2023, then rose by 0.79% to $100.3 million in 2024, then slumped by 50.74% to $49.4 million in 2025, then rose by 0.56% to $49.7 million in 2026.
- Business Quant data shows LXRX's Non-Current Debt at $49.7 million in Q1 2026, $49.4 million in Q4 2025, and $56.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | 51.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.44 Mn |
| Mar 31, 2026 | 49.68 Mn |
| Dec 31, 2025 | 49.41 Mn |
| Sep 30, 2025 | 56.51 Mn |
| Jun 30, 2025 | 56.10 Mn |
| Mar 31, 2025 | 58.64 Mn |
| Dec 31, 2024 | 100.30 Mn |
| Sep 30, 2024 | 99.90 Mn |
| Jun 30, 2024 | 99.50 Mn |
| Mar 31, 2024 | 99.90 Mn |
| Dec 31, 2023 | 99.51 Mn |
| Sep 30, 2023 | 99.27 Mn |
| Jun 30, 2023 | 98.80 Mn |
| Mar 31, 2023 | 48.80 Mn |
| Dec 31, 2022 | 48.58 Mn |
| Sep 30, 2022 | 23.78 Mn |
| Jun 30, 2022 | 23.60 Mn |
| Mar 31, 2022 | 23.48 Mn |
| Sep 30, 2020 | 11.63 Mn |
| Jun 30, 2020 | 234.81 Mn |